WO2004022040A2 - Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist - Google Patents

Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist Download PDF

Info

Publication number
WO2004022040A2
WO2004022040A2 PCT/CA2003/001340 CA0301340W WO2004022040A2 WO 2004022040 A2 WO2004022040 A2 WO 2004022040A2 CA 0301340 W CA0301340 W CA 0301340W WO 2004022040 A2 WO2004022040 A2 WO 2004022040A2
Authority
WO
WIPO (PCT)
Prior art keywords
administered
chemotherapeutic agent
patient
group
diphenyl compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2003/001340
Other languages
English (en)
French (fr)
Other versions
WO2004022040A3 (en
Inventor
Lorne J. Brandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Priority to CA002497180A priority Critical patent/CA2497180A1/en
Priority to EP03793535A priority patent/EP1536779A2/en
Priority to BR0314097-0A priority patent/BR0314097A/pt
Priority to US10/526,563 priority patent/US20060089317A1/en
Priority to MXPA05002465A priority patent/MXPA05002465A/es
Priority to JP2004533120A priority patent/JP2006516533A/ja
Priority to AU2003266047A priority patent/AU2003266047A1/en
Publication of WO2004022040A2 publication Critical patent/WO2004022040A2/en
Publication of WO2004022040A3 publication Critical patent/WO2004022040A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • R 2 is a diethylamino group.
  • This compound namely N,N-diethyl-2-[4-(phenylmethyl)- phenoxy]ethanamine, which may be in the form of the free base or in the form of its hydrochloride or other pharmaceutically-acceptable salt, is abbreviated herein as DPPE.
  • DPPE N,N-diethyl-2-[4-(phenylmethyl)- phenoxy]ethanamine
  • DPPE diphenylmethyl-2-[4-(phenylmethyl)- phenoxy]ethanamine
  • DPPE hydrochloride or other pharmaceutically-acceptable salt
  • Other substitutents may be provided on the benzene rings in addition to the halogen atoms, for example, an imidazole group.
  • the diphenyl compound preferably is used in an amount of about 3 to about 10 mg kg of patient administered intravenously over a period of about 30 to about 90 minutes prior to administration of the chemotherapeutic agents and continuing for the period of administration of the chemotherapy agents.
  • the present invention provides an improved method of treatment of metastatic breast cancer using a combination of anthracyclines and taxanes. Modifications are possible within the scope of the invention. TABLE I

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/CA2003/001340 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist Ceased WO2004022040A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002497180A CA2497180A1 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
EP03793535A EP1536779A2 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines and taxanes
BR0314097-0A BR0314097A (pt) 2002-09-04 2003-09-03 Uso de agentes antraciclina quimioterápicos e agentes quimioterápicos de taxano
US10/526,563 US20060089317A1 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, and taxanes
MXPA05002465A MXPA05002465A (es) 2002-09-04 2003-09-03 Tratamiento del cancer de mama metastatico con antraciclinas y taxanos.
JP2004533120A JP2006516533A (ja) 2002-09-04 2003-09-03 アントラサイクリンおよびタキサンによる転移性乳癌の治療
AU2003266047A AU2003266047A1 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40767902P 2002-09-04 2002-09-04
US60/407,679 2002-09-04

Publications (2)

Publication Number Publication Date
WO2004022040A2 true WO2004022040A2 (en) 2004-03-18
WO2004022040A3 WO2004022040A3 (en) 2004-04-29

Family

ID=31978506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001340 Ceased WO2004022040A2 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist

Country Status (11)

Country Link
US (1) US20060089317A1 (https=)
EP (1) EP1536779A2 (https=)
JP (1) JP2006516533A (https=)
KR (1) KR20050086415A (https=)
CN (1) CN1694691A (https=)
AU (1) AU2003266047A1 (https=)
BR (1) BR0314097A (https=)
CA (1) CA2497180A1 (https=)
MX (1) MXPA05002465A (https=)
RU (1) RU2005109421A (https=)
WO (1) WO2004022040A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063574T3 (es) * 1990-12-17 1995-01-01 Univ Manitoba Metodo de tratamiento mejorado para el cancer.
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
PL369792A1 (en) * 2001-11-01 2005-05-02 Ym Biosciences, Inc. Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy
US20050119263A1 (en) * 2001-11-09 2005-06-02 Vincent Mark D. Treatment of breast cancer

Also Published As

Publication number Publication date
EP1536779A2 (en) 2005-06-08
KR20050086415A (ko) 2005-08-30
JP2006516533A (ja) 2006-07-06
AU2003266047A8 (en) 2004-03-29
BR0314097A (pt) 2005-07-19
CN1694691A (zh) 2005-11-09
AU2003266047A1 (en) 2004-03-29
CA2497180A1 (en) 2004-03-18
MXPA05002465A (es) 2005-12-14
RU2005109421A (ru) 2005-10-20
WO2004022040A3 (en) 2004-04-29
US20060089317A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
Hodi et al. Phase II study of paclitaxel and carboplatin for malignant melanoma
AU2003244646B2 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
JP2001247459A (ja) 癌の組み合わせ療法
PL192544B1 (pl) Zastosowanie czynnika zwiększającego doustną biodostępność, zestaw farmaceutyczny i kompozycja farmaceutyczna do podawania doustnego
JP2009536956A (ja) 抗癌治療法
MX2011011765A (es) Combinacion antitumoral que comprende cabazitaxel y capecitabina.
JP2000505796A (ja) エダトレキセートおよびタキサン誘導体（例えばパクリタキセル）を用いる癌を処置するための組み合わせ治療方法
EP1536779A2 (en) Treatment of metastatic breast cancer with anthracyclines and taxanes
US20050119263A1 (en) Treatment of breast cancer
US20080318880A1 (en) Neoadjuvant treatment of Breast Cancer
WO2004022044A1 (en) Use of a combination of a taxane with dppe for the treatment of cancer
US20060142287A1 (en) Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer
JP2004519409A (ja) ガン治療を促進するためのプロパルギルアミン含有組成物
AU2002340668A1 (en) Treatment of breast cancer
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
CN120420332A (zh) 一种含mTOR抑制剂的组合物及其用途
Inbar et al. Chemofiltration (CF) for locally advanced cancer
Brodin et al. Sensitivity to cytotoxic drugs in biopsy material from lung carcinomas
Cummings et al. Positive correlation between tumour drug disposition and the activity of doxorubicin microspheres: Implications for the drugs in vivo mechanism of action
Merlin et al. Comparison of P-glycoprotein expression and daunorubicin cellular accumulation in adult and childhood acute leukemias
Merlin et al. Comparative evaluation of S9788, verapamil and cyclosporine a on multidrug resistant cells from patients with hematological malignancies
Kaburagi et al. Alternative daily subcutaneous injections of4ig/kg lenograstim in lung cancer case

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2497180

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004533120

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057003797

Country of ref document: KR

Ref document number: PA/a/2005/002465

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1104/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003793535

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005109421

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 20038247461

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003793535

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006089317

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10526563

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020057003797

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 10526563

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003793535

Country of ref document: EP